Publication:
Trimethylamine-N-oxide and 5-year mortality: the role of gut microbiota-generated metabolite from the CORE-Thailand cohort

0
0

Issued Date

2024-12-01

Resource Type

Article

eISSN

20452322

DOI

10.1038/s41598-024-71479-z

Scopus ID

2-s2.0-85203683604

Pubmed ID

39261513

Journal Title

Scientific Reports

Volume

14

Issue

1

Rights Holder(s)

SCOPUS

Bibliographic Citation

Scientific Reports Vol.14 No.1 (2024)

Suggested Citation

Senthong V., Kiatchoosakun S., Wongvipaporn C., Phetcharaburanin J., Sritara P., Phrommintikul A., Worasuwannarak S., Dutsadeevettakul S., Suksuphew S., Cheewatanakornkul S., Suwanugsorn S., Taweesangsuksakul P., Senthong V., Tatsanaviva P., Kiatchoosakun S., Wongvipaporn C., Simtharakaew T., Sukanandachai B., Dinchuthai P., Kositchaiwat J., Siriaree K., Siriwattana K., Chotechuang Y., Phengtham U., Watcharasaksilp K., Buranapin S., Prasertwitayakij N., Wongcharoen W., Phrommintikul A., Paspitsanu P., Laksomya T., Maraprasertsak M., Jai-Aue S., Wongtheptien W., Deerochanawong C., Hutayanon P., Changsirikulchai S., Porapakkham P., Kanaderm C., Suraamornkul S., Satirapoj B., Tiyanon W., Rattanasumawong K., Wongpraparut N., Boonyasirinant T., Krittayaphong R., Udol K., Lertsuwunseri V., Satitthummanid S., Boonyaratavej S., Srimahachota S., Yamwong S., Sritara P. Trimethylamine-N-oxide and 5-year mortality: the role of gut microbiota-generated metabolite from the CORE-Thailand cohort. Scientific Reports Vol.14 No.1 (2024). doi:10.1038/s41598-024-71479-z Retrieved from: https://hdl.handle.net/20.500.14740/20231

Title

Trimethylamine-N-oxide and 5-year mortality: the role of gut microbiota-generated metabolite from the CORE-Thailand cohort

Author(s)

Senthong V.
 Kiatchoosakun S.
 Wongvipaporn C.
 Phetcharaburanin J.
 Sritara P.
 Phrommintikul A.
 Worasuwannarak S.
 Dutsadeevettakul S.
 Suksuphew S.
 Cheewatanakornkul S.
 Suwanugsorn S.
 Taweesangsuksakul P.
 Senthong V.
 Tatsanaviva P.
 Kiatchoosakun S.
 Wongvipaporn C.
 Simtharakaew T.
 Sukanandachai B.
 Dinchuthai P.
 Kositchaiwat J.
 Siriaree K.
 Siriwattana K.
 Chotechuang Y.
 Phengtham U.
 Watcharasaksilp K.
 Buranapin S.
 Prasertwitayakij N.
 Wongcharoen W.
 Phrommintikul A.
 Paspitsanu P.
 Laksomya T.
 Maraprasertsak M.
 Jai-Aue S.
 Wongtheptien W.
 Deerochanawong C.
 Hutayanon P.
 Changsirikulchai S.
 Porapakkham P.
 Kanaderm C.
 Suraamornkul S.
 Satirapoj B.
 Tiyanon W.
 Rattanasumawong K.
 Wongpraparut N.
 Boonyasirinant T.
 Krittayaphong R.
 Udol K.
 Lertsuwunseri V.
 Satitthummanid S.
 Boonyaratavej S.
 Srimahachota S.
 Yamwong S.
 Sritara P.

Author's Affiliation

Ramathibodi Hospital
 Siriraj Hospital
 Faculty of Medicine, Chiang Mai University
 Nakornping Hospital
 Lampang Hospital
 Suranaree University of Technology
 Faculty of Medicine, Khon Kaen University
 Faculty of Medicine, Prince of Songkla University
 Police General Hospital
 Naresuan University
 Vajira Hospital
 Khon Kaen University
 Faculty of Medicine Ramathibodi Hospital, Mahidol University
 Faculty of Medicine, Thammasat University
 Maharaj Nakhon Ratchasima Hospital
 Khon Kaen Regional Hospital
 Mahidol University
 Burapha University
 Phramongkutklao College of Medicine
 Faculty of Medicine, Srinakharinwirot University
 Rajavithi Hospital
 Faculty of Medicine, Chulalongkorn University
 Central Chest Institute of Thailand
 Phrapokklao Hospital
 Phrae Hospital
 Chiangrai Prachanukroh Hospital
 Pranangklao Hospital

Corresponding Author(s)

Senthong V.

Other Contributor(s)

Srinakharinwirot University

Abstract

The gut microbiota metabolite trimethylamine-N-oxide (TMAO)—derived from dietary phosphatidylcholine—is mechanistically linked to cardiovascular disease (CVD) and increased cardiovascular risk. This study examined the relationship between fasting plasma TMAO levels and 5-year all-cause mortality in a cohort of patients at high risk of cardiovascular events (CORE-Thailand Registry). Of the 134 patients, 123 (92%) had established cardiovascular disease, and 11 (8%) had multiple risk factors. Fasting plasma TMAO levels were measured using nuclear magnetic resonance spectroscopy. Within this prospective cohort study, the median TMAO was 3.81 μM [interquartile range (IQR) 2.89–5.50 μM], with a mean age of 65 ± 11 years; 61% were men, and 39.6% had type II diabetes. Among 134 patients, 65 (49%) were identified as the high-TMAO group (≥ 3.8 μM), and 69 (51%) were identified as the low-TMAO group (< 3.8 μM). After a median follow-up of 58.8 months, the high-TMAO group was associated with a 2.88-fold increased mortality risk. Following adjustment for traditional risk factors, high-sensitivity cardiac troponin-T, estimated glomerular filtration rate, angiotensin-converting enzyme (ACEI), or angiotensin-receptor blocker (ARB) use, the high-TMAO group remained predictive of 5-year all-cause mortality risk (the high-TMAO vs. the low-TMAO group, adjusted hazard ratio 2.73, 95% CI 1.13–6.54; P = 0.025). Among Thai patients at high risk of cardiovascular events, increased plasma TMAO levels portended greater long-term mortality risk.

Keyword(s)

Multidisciplinary

View online Resources

Research Projects

Organizational Units

Journal Issue

URI

https://hdl.handle.net/20.500.14740/20231

Collections

Scopus: Year 2024

Endorsement

Review

Supplemented By

Referenced By